Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Shareholder Meeting (April 2016)
15 slides from Bristol-myers Squibb's shareholder meeting presentation, Apr 18, 2016
Slide 1: Diversified Specialty BioPharma Company
Diversified Specialty BioPharma Company Bristol-Myers Squibb recently emerged from a transformation to a diversified specialty biopharma company, combining the agility of a biotech company with the resources and stability of a large pharmaceutical company Key Therapeutic Areas Oncology Immunoscience
Slide 2: Completion of Successful Leadership Transition
Completion of Successful Leadership Transition On May 5, 2015, Giovanni Caforio succeeded Lamberto Andreotti as CEO and Mr. Andreotti became our Non-Executive Chairman Non-Executive Chairman Concurrently, Togo D. West, Jr. assumed the Lead Independent Director role, having been unanimously elected b
Slide 3: Strong Revenue Growth and Value Creation
Strong Revenue Growth and Value Creation We have achieved significant growth across key product portfolios, building on the strategic foundation established by our transformation to a diversified specialty bio-pharma company, which we believe will continue to drive shareholder value creation 2015 Ke
Slide 4: Opdivo Unprecedented 2015 Achievements
Opdivo Unprecedented 2015 Achievements Demonstrated improved overall survival Faster than anticipated market adoption small cell lung non-small cell Kidcer previously regimen for treatment of advanced lung cancer cancer ncer n Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Quarter Q2 Opdivo Sales $122M
Slide 5: Executive Compensation Framework
Executive Compensation Framework Our Compensation Philosophy and Structure 2015 Target Total CEO Compensation P ay for P erform an ce A substantial proportion of our executives’ pay is variable, at-risk based on our financial and operation results and delivered in the form of equity, supporting alig
Slide 6: Compensation Program Evolution in 2016
Compensation Program Evolution in 2016 During 2015, our Board and management engaged with shareholders representing over 40% of shares outstanding, gaining valuable feedback on our compensation practices Concurrently, we performed an in-depth review of our compensation program in the context of our
Slide 7: Incentive Target Setting Process
Incentive Target Setting Process Our compensation program and incentive targets are designed to motivate our executives to deliver high performance with the highest integrity in a competitive labor market Timeline of Incentive Target Setting & 2015 Guidance Refinements NOT FOR PRODUCT PROMOTIONAL US
Slide 8: 2015 Compensation Plan Structure
2015 Compensation Plan Structure product approvals late-stage pipeline Candidates, First in Confidence, Regional NOT FOR PRODUCT PROMOTIONAL USE 9 Market Share Units (40%) Rewards creation of incremental shareholder value Provides a mix of short, medium and long-term performance periods Multi-year v
Slide 9: Highly Engaged Board with Broad Experience
Highly Engaged Board with Broad Experience Comprehensive Board Expertise Healthcare Industry 8 8 7 8 11 9 Gov/Academia 4 6 10 Range of Tenure, Diversity & Perspectives 4 years (5 irectors) >10 years (1 Director) 5-10 years (5 Directors) = New Since 2013 * Board Committees as of date of 2016 Annual M
Slide 10: Committed to Sound Corporate Governance
Committed to Sound Corporate Governance Board Accountability and Stockholder Rights Proactive shareholder engagement Proxy access shareholder right The Board continues to place a high priority on engagement with our shareholders Annual election of Directors Ability to call special meetings (25%) Maj
Slide 11: We Value Your Support at Our 2016 Annual Meeting
We Value Your Support at Our 2016 Annual Meeting 1 Shareholder base data as of April 11, 2016. NOT FOR PRODUCT PROMOTIONAL USE 12 Shareholder Proposal Considerations The request to reduce our special meeting ownership threshold from 25% to 15% is unnecessary given: –our history of responsiveness to
Slide 12: Forward-Looking and Non-GAAP Information
Forward-Looking andNon-GAAPInformation This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ mate
Slide 13: Appendix A
Appendix A NOT FOR PRODUCT PROMOTIONAL USE 14
Slide 14: 2015 Full Year EPS GAAP to Non-GAAP Reconciliation
2015 FULL YEAR EPS GAAP to NON-GAAP RECONCILIATION BRISTOL-MYERS SQUIBB COMPANY 2015 FULL YEAR EPS GAAP to NON-GAAP RECONCILIATION Full Year 2015 GAAP Diluted EPS Specified Items: Downsizing and streamlining of worldwide operations Upfront and milestone payments, net Pension Related items Impairment
Slide 15: 2015 Full Year EPS GAAP to Non-GAAP Reconciliation
2015 FULL YEAR EPS GAAP to NON-GAAP RECONCILIATION BRISTOL-MYERS SQUIBB COMPANY 2015 FULL YEAR EPS GAAP to NON-GAAP RECONCILIATION GAAP Diluted EPS $0.93 Specified Items: Downsizing and streamlining of worldwide operations 0.07 Upfront and milestone payments, net 1.00 Pension Related items 0.10 Impa
Bristol-Myers Squibb — Shareholder Meeting (April 2016) on 6ix